GALDERMA
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL™ technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
ADRIAN MURPHY HEAD OF GLOBAL OPERATIONS GALDERMA
|
Galderma’s center of excellence in Uppsala is one of the company’s four state-of-the-art manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions. The new facility—scheduled for completion by the end of 2025—will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma’s growth strategy and its environment, social and governance (ESG) roadmap.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain. Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio – part of the broadest injectable aesthetics portfolio on the market.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618347979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Acquires Majority Stake in Idrica to Empower Water Utilities With Intelligent Solutions10.12.2024 13:15:00 CET | Press release
Companies will further integrate solutions that help utilities accelerate digitalization and tackle critical challenges such as water scarcity and aging infrastructure Global water solutions company Xylem (NYSE: XYL) today announced that it has acquired a majority stake in Idrica, a leader in water data management and analytics, to empower water utilities with intelligent solutions for their most critical challenges. Xylem Vue, which combines Xylem’s existing digital water solutions portfolio with Idrica’s technology platform, empowers customers to address critical challenges such as water scarcity and aging infrastructure with real-time insights. Today’s move will enable the two companies to further integrate their solutions and create a simpler, more powerful customer experience. “Deepening our partnership with Idrica is a critical piece of our strategy to deliver intelligent solutions to our customers,” said Matthew Pine, CEO of Xylem. “Together, we can help them see deeper into the
Xsolla Strengthens Game Development Opportunities in the UK With Office Hours at Red Bull Gaming Sphere Partnership10.12.2024 10:00:00 CET | Press release
Xsolla Empowers Indie and Mid-Tier Developers with Payment Solutions and Direct-to-Consumer Opportunities Xsolla, a global video game commerce company, is excited to announce its role as the Official Supporting Partner (Payment Solutions) for Office Hours at Red Bull Gaming Sphere’s December 11th event. This collaborative event, hosted at the Red Bull Gaming Sphere in Shoreditch, London, offers a unique combination of co-working spaces, expert panel discussions, and game showcases to foster new opportunities for developers to grow, learn, and expand their reach in the UK and globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210890933/en/ (Graphic: Xsolla) “We believe in providing equal access to opportunities for everyone and are committed to supporting efforts to help grow the local game development community in the UK,” said Chris Meredith, SVP EMEA at Xsolla. “Through our advanced payment solutions, we aim to em
YANGGUOFU Malatang’s European MALA GALA Debuts in Berlin: Culture as Wings, Fragrance Spreads Worldwide10.12.2024 09:44:00 CET | Press release
The YANGGUOFU Malatang European Spicy Festival, “MALA GALA,” was grandly opened in Berlin on December 5th, accompanied by a comprehensive upgrade of the brand image. With the core concept of “Culture as Wings, Fragrance Spreads Worldwide,” it aims to spread the culture of Eastern cuisine overseas. Since the first store was established in Spain in 2023, YANGGUOFU has quickly opened branches in 10 European countries, winning widespread acclaim. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241206278177/en/ MALA GALA (Photo: Business Wire) The MALA GALA marks the brand’s deep expansion into the European market with the simultaneous opening of new stores in Berlin and Prague. Moving forward, new stores in five countries and ten cities will be linked, and the brand’s sixth-generation stores will officially debut across the European continent, from the UK, France, Germany, and Italy to the Czech Republic. To deepen cultural excha
AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK10.12.2024 09:29:00 CET | Press release
AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210380168/en/ Maximilien Levesque, CEO and Cofounder of AQEMIA (left) and Emmanuelle Martiano Rolland, COO and Cofounder of AQEMIA (Photo: Business Wire) The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows the successful validation of AQEMIA’s drug discovery platform through outstanding results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The funding will support AQEMIA’s development goals, including preparations for clinic
Kioxia Develops OCTRAM (Oxide-Semiconductor Channel Transistor DRAM) Technology10.12.2024 09:22:00 CET | Press release
Kioxia Corporation, a world leader in memory solutions, today announced the development of OCTRAM (Oxide-Semiconductor Channel Transistor DRAM), a new type of 4F2 DRAM, comprised of an oxide-semiconductor transistor that has a high ON current, and an ultra-low OFF current, simultaneously. This technology is expected to realize a low power DRAM by bringing out the ultra-low leakage property of the InGaZnO*1 transistor. This was first announced at the IEEE International Electron Devices Meeting (IEDM) held in San Francisco, CA on December 9, 2024. This achievement was jointly developed by Nanya Technology and Kioxia Corporation. This technology has the potential to lower power consumption in a wide range of applications, including AI and post-5G communication systems, and IoT products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209099702/en/ Fig.1: Cross-sectional TEM image for the InGaZnO vertical transistor (Photo: Bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom